Brief: Blueprint Medicines Q1 Net Income USD 89.136 Million Vs. IBES Estimate USD -101.1 Million
02/05/2024 12:01
May 02 (Reuters) - Blueprint Medicines Q1 EPS USD 1.4 vs. IBES estimate USD -1.66. * Q1 product revenue USD 92.525 million * Q1 pretax profit USD 89.316 million vs. IBES estimate USD -102.2 million * Q1 basic EPS USD 1.45 * Q1 operating expenses USD 174,939,174.939 million
Recent news on Blueprint Medicines
See all newsBrief: Sanofi Announces Extension Of Blueprint Tender Offer
Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G